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We synthesized a series of compounds bearing pharmacologically important 1,3,4-oxadiazole 
and piperidine moieties. Spectral data analysis by 1H-NMR, 13C-NMR, IR and EI-MS was used to 
elucidate the structures of the synthesized molecules. Docking studies explained the different types 
of interaction of the compounds with amino acids, while bovine serum albumin (BSA) binding 
interactions showed their pharmacological effectiveness. Antibacterial screening of these compounds 
demonstrated moderate to strong activity against Salmonella typhi and Bacillus subtilis but only weak 
to moderate activity against the other three bacterial strains tested. Seven compounds were the most 
active members as acetyl cholinesterase inhibitors. All the compounds presented displayed strong 
inhibitory activity against urease. Compounds 7l, 7m, 7n, 7o, 7p, 7r, 7u, 7v, 7x and 7v were highly 
active, with respective IC
50
 values of 2.14±0.003, 0.63±0.001, 2.17±0.006, 1.13±0.003, 1.21±0.005, 
6.28±0.003, 2.39±0.005, 2.15±0.002, 2.26±0.003 and 2.14±0.002 µM, compared to thiourea, used as 
the reference standard (IC
50
 = 21.25±0.15 µM). These new urease inhibitors could replace existing 
drugs after their evaluation in comprehensive in vivo studies.
Keywords: 1,3,4-Oxadiazole. Acetylcholinesterase (AChE) inhibition. Antibacterial activity. 
Piperidine. Sulfonamide. Urease inhibition.
INTRODUCTION
1,3,4-Oxadiazole is a pharmacologically important 
heterocyclic core, and a number of biological activities 
have been described for derivatives with this moiety. 
Among these bioactivities, the most important ones are 
antibacterial (Li et al., 2014), anti-inflammatory (Omar, 
Mahfouz, Rahman, 1996), anticancer (Kumar et al., 
2009), antihepatitis (Tan et al., 2006), antitumor (Zhang 
et al., 2014) and antiproliferative (El-Din et al., 2015), 
among many other activities. Another key bioactive 
heterocyclic core is piperidine. The various bioactivities 
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of this nucleus have been evaluated via the synthesis of 
a number of piperidine derivatives (Sanchez-Sancho, 
Herrandón, 1998). Compounds bearing the piperidine 
nucleus are associated with anesthetic activity, treatment 
of cocaine abuse, and controlling plasma glucose and 
insulin (Nithiya, Karthik, Jayabharathi, 2011). Among 
the different functionalities, sulfamoyl is one of the 
most important ones regarding pharmacological and 
therapeutic potential. The pharmacological behavior 
of this moiety is mainly related to antibacterial action, 
enzyme inhibition, cancer chemotherapy, hypoglycemic 
activity, diuretic action and many other uses (Aziz-ur-
Rehman et al., 2011).
The synthesized compounds were evaluated 
for antibacterial activity, enzyme inhibitory activity 
(acetylcholinesterase (AChE) and urease) and bovine 
serum albumin (BSA) binding. The bacterial strains 
taken into account were Salmonella Typhi, Escherichia 
coli, Pseudomonas aeruginosa, Staphylococcus aureus 
and Bacillus subtilis, which are involved in enteric fever 
(Bhattacharya, Das, Choudhury, 2011), food poisoning 
(Vogt, Dippold, 2005), chronic infection (Pressler 
et al., 2011), pathogen adherence to extracellular 
matrix or plasma proteins (Harris, Foster, Richards, 
2002) and skin allergy or hypersensitivity (Barbe 
et al., 2009), respectively. AChE (EC 3.1.1.7), a serine 
hydrolase, is known to hydrolyze the neurotransmitter 
acetylcholine leading to termination of nerve impulse in 
cholinergic synapses and Alzheimer’s disease (Tougu, 
2001). Urease (EC 3.5.1.5), urea amidohydrolase, is 
actively involved in pyelonephritis, peptic ulceration, 
kidney stones, hepatic encephalopathy, urolithiasis and 
urinary catheter incrustation (Lodhi et al., 2007). Blood 
plasma proteins act carriers for the transportation of 
drugs and other substances throughout the body (Wani 
et al., 2018). The most abundant plasma protein is 
albumin which binds with metabolites and ligands. The 
pharmacokinetic and pharmacodynamic properties can 
be understood through the binding interaction of serum 
albumin and drug molecules. BSA is widely used in this 
regard because of high resemblance in structure with 
human serum albumin (HSA) (Wani et al., 2017a; Wani 
et al., 2017b; Wani et al., 2017c).
Chemists and pharmacologists have been 
working extensively on the synthesis of new 
molecules to combat and control various diseases. In 
this regard, two heterocyclic cores, 1,3,4-oxadiazole 
and piperidine, and the sulfamoyl functionality of 
sulfonamides have been introduced as bioactive 
structures. The notable pharmacological behavior of 
these three functionalities prompted us to synthesize 
some new molecules bearing all these three moieties. 
As an extension of our previous work (Nafeesa et al., 
2015), the synthesized compounds were evaluated for 
their pharmacological potential as antibacterial agents 
and AChE and urease inhibitors.
MATERIAL AND METHODS
General
The IR spectra were recorded using KBr pellet 
method on a Jasco-320-A spectrometer with wave 
number in cm-1. Mass spectra (EI-MS) were recorded on 
a JMS-HX-110 spectrometer with a data system. Proton 
and carbon nuclear magnetic resonance spectra were 
recorded in CDCl
3
 solvent on a Bruker spectrometer 
operating at 300 and 400 MHz with chemical shifts 
in ppm and coupling constant in hertz (Hz). Purity of 
synthesized compounds was confirmed using thin layer 
chromatography (TLC), carried out on pre-coated silica 
gel G-25-UV
254 
aluminum plates, run under different 
solvent systems with varying proportions of ethyl acetate 
and n -hexane and visualized using a 254-nm UV lamp. 
Melting points of the synthesized compounds were 
recorded on a Griffin and George meting point apparatus 
with open capillary tube and were uncorrected. 
Preparation of ethyl 1-[(4-chlorophenyl) 
sulfonyl] piperidin-4-carboxylate (3)
Ethyl isonipecotate (2; 0.003 mol) was dispersed in 
40 mL of distilled water in a 250-mL round-bottom (RB) 
flask followed by addition of 4-chlorophenylsulfonyl 
chloride (1; 0.003 mol). During gradual addition of 1, the 





. The mixture was stirred for 4 hours and 
monitored by TLC. Dilute HCl (2-3 mL) was added with 
continuous stirring to adjust pH at 6.0, and the mixture 
allowed to stand for 20-30 minutes. The precipitates were 
filtered out, washed with cold distilled water and dried. 
Preparation of 1-[(4-chlorophenyl)sulfonyl]
piperidin-4-carbohydrazide (4)
Compound 3 (0.0025 mol) was dissolved in 35 mL 
of methanol in a 250-mL RB flask, and 80% hydrazine 
hydrate (12 mL) was added, followed by refluxing for 
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3 hours. The reaction was monitored by TLC. Excess 
solvent was evaporated off and the precipitate was 
filtered out, washed with cold distilled water and dried. 
Preparation of 5-{1-[(4-chlorophenyl)sulfonyl]
piperidin-4-yl}-2-mercapto-1,3,4-oxadiazole (5)
Compound 4 (0.002 mol) was dissolved in 35 mL of 
ethanol in a 250-mL RB flask followed by the addition 
of KOH (0.002 mol) and refluxing for 30 minutes. After 
the addition of CS
2
 (0.004 mol), the reaction mixture 
was refluxed for 6 hours and monitored by TLC. Excess 
chilled distilled water (70 mL) was added and pH was 
adjusted to 6 with dilute HCl (3-4 mL) to obtain the 
precipitate. The precipitate was filtered out, washed with 
cold distilled water and dried.
General procedure for the synthesis of 
5-{1-[(4-chlorophenyl)sulfonyl]piperidin-4-yl}-
2-[(alkyl/aralkyl)thio]-1,3,4-oxadiazole (7a-z)
Compound 5 (0.0015 mol) was dissolved in N,N-
dimethyl formamide (DMF, 15 mL) in a 50-mL RB 
flask and lithium hydride (0.0015 mol) was added. The 
reaction mixture was stirred for 30 minutes. Equimolar 
alkyl/aralkyl halides, 6a-z, were then added to the 
reaction mixture, which was further stirred for 4-5 
hours. The reaction was monitored by TLC. Excess cold 
distilled water was added to obtain the precipitated final 
compounds, 7a-z, which were recovered by filtration, 
washed with distilled water and dried.
Biological activity assays
Antibacterial activity assay
Antibacterial activity was determined under aseptic 
conditions in sterile 96-well microplates. The method 
is based on the increase in the absorbance of the broth 
medium with microbial cell population during log phase 
growth (Nafeesa et al., 2015). Ciprofloxacin was used as 
the reference standard.
Acetyl cholinesterase inhibition assay
AChE inhibitory activity was determined by 
following the reported method (Mahernia et al., 2015) 





(pH 7.7), 10 µL of test compound (0.5 mM well-1) and 
10 µL AChE (0.005 mM) was prepared. Absorbance of 
the mixture at 405 nm was recorded, and the mixture 
was then incubated for 15 min at 35 ºC. The enzyme 
reaction was started by the addition of 10 µL of 0.5 
mM acetylthiocholine iodide as substrate and 10 µL 
of 0.5 mM DTNB. After 15 minutes of incubation, the 
absorbance was measured at 405 nm by using a Synergy 
HT 96-well plate reader (BioTek, USA). Eserine (0.5 
mM) was used as a standard for the positive control. 
Percent inhibition was calculated as follows:
Inhibition (%) = x 100
Control – Text
Control
where Test is the activity in the presence of compound 
of concern, while Control is the activity in the absence 
of inhibitor. 
Urease inhibition assay
A 985-µL reaction mixture containing test 
compound (0 to 100 µL), urea (850 µL) and phosphate 
buffer (100 mM, pH 7.4) was prepared to evaluate urease 
inhibitory activity using a previously reported method 
(Chapdelaine, Tremblay, Dube, 1978). The reaction was 
started by the addition of 15 µL of urease enzyme and 
allowed to proceed for 60 minutes at 37 °C. A volume 
of 500 µL of solution A containing 0.5 g phenol and 2.5 
mg sodium nitroprusside in 50 mL of distilled water and 
equi-volume of solution B containing 250 mg sodium 
hydroxide and 820 µL of 5% sodium hypochlorite in 50 
mL of distilled water was used to measure the extent of 
reaction after incubation for another 30 minutes. Urease 
activity before inhibition was taken as 100% control 
activity. The formula used to calculate % inhibition was 
similar as for AChE. 
Statistical analysis
The results are presented as mean ± SEM for 
triplicate calculations after statistical analysis executed 
in MS Excel 2010. Minimum inhibitory concentration 
(MIC) for antibacterial activity and concentration 
for 50% inhibition (IC
50
) for AChE inhibition were 
determined using suitable dilutions for each sample, 
and the results were obtained using EZ-Fitz software 
(Perrella Scientific Inc., USA). GraphPad Prism 5 
software was used to calculate the IC
50
 values for urease.
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Computational studies 
Initial processing of proteins and ligand preparation
To study the interaction of ligands in the active 
site of AChE by using chemoinformatics, the co-crystal 
3D-structure recombinant human AChE (Ghersi, 
Sanchez, 2011) in complex with donepezil (PDB entry: 
4EY7) was obtained from the RCSB Protein Data Bank 
(PDB). All protein structures from PDB were further 
processed prior to docking studies using structure 
preparation tools included in biopolymer module of 
SYBYL-X 1.3. Missing hydrogens were added, charges 
were applied and atom types were assigned according 
to AMBER 7 FF99 force field followed by the energy 
minimization using the Powell algorithm with a 
convergence gradient of 0.5 kcal (mol Å)-1 for 1000 
cycles. Moreover, the 3D structures of the inhibitors 
studied were constructed using the SKETCH module 
in Sybyl-X 1.3 followed by energy minimization using 
Tripos force field with Gasteiger-Hückel charge. 
Molecular docking
The molecular docking studies were performed 
with the Surflex-Dock module of SybylX-1.3 (Jain, 
Dock, 2007). The experimentally determined active 
conformation of donepezil in the AChE active site was 
used as initial conformation to define the potential binding 
pocket by protomol (an idealized active site) generation 
(Chohan et al., 2016a). The defined active site can be used 
to generate several putative poses of ligand (Chohan et 
al., 2016b). These putative poses of ligand were ranked 
using the Hammerhead scoring function (Holt, Chaires, 
Trent, 2008). All parameters determining the extent 
of protomol were kept at default (threshold = 0.50 and 
bloat=0). Finally, the synthesized compounds were then 
individually docked in the idealized active site of AChE 
with the “whole” molecular alignment algorithm, and 
twenty top-ranked docked poses were finally saved for 
each inhibitor.
Protein drugs interaction studies
BSA binding interactions using fluorescence measurements
For the determination of the BSA quenching 
constant, fluorometric titration of a solution of BSA (3 
mL, 3 µM) in phosphate buffer (20 mM, pH 7.4) with the 
synthesized compounds (1 mg/mL in DMSO solvent) 
was carried out. The solutions were excited at 295 nm 
and the emission of the BSA solution with and without 
test compound was recorded at 336 nm and 298 K. For 
site-selective binding studies, fluorometric titration 
of BSA solution (3 mL, 3 µM) with and without site 
markers (ibuprofen or warfarin) was carried out with 
the solutions of synthesized compounds (1 mg/mL in 
DMSO). The solutions were scanned using an excitation 




Off-white amorphous solid; Yield: 79 %; M.P.: 102-










; Mol. weight: 399 
gmol-1; IR (KBr, υmax, cm
-1): 3130 (Ar C-H), 1678 (Al 
C=C), 1658 (C=N), 1594 (Ar C=C), 1517 (N=O), 1446 
(S=O), 1228, 1025 (C-O-C), 1148 (C-N), 655 (C-Cl), 622 
(C-S); 1H-NMR (CDCl
3
, 400 MHz): δ (ppm) 7.86 (d, J = 
8.4 Hz, 2H, H-2” & H-6”), 7.50 (d, J = 8.4 Hz, 2H, H-3” 
& H-5”), 5.99-5.90 (m, 1H, H-2”’), 5.30 (dd, J = 16.8, 0.8 
Hz, 1H, H
a
-3”’), 5.18 (d, J = 10.4 Hz, 1H, H
b
-3”’), 3.81 (d, 
J = 7.2 Hz, 2H, H-1”’), 3.66-3.63 (m, 2H, He-2’ & He-6’), 
2.92-2.85 (m, 1H, H-4’), 2.63 (dt, J = 12.4, 2.8 Hz, 2H, 
Ha-2’ & Ha-6’), 2.14-2.09 (m, 2H, He-3’ & He-5’), 2.02-
1.92 (m, 2H, Ha-3’ & Ha-5’); EI-MS (m/z): 401 [M+2]
+, 


































Light brown crystalline solid; Yield: 83 %; M.P.: 










; Mol. weight: 
387 gmol-1; IR (KBr, υmax, cm
-1): 3030 (Ar C-H), 1688 
(C=N), 1599 (Ar C=C), 1519 (N=O), 1466 (S=O), 
1220, 1029 (C-O-C), 1168 (C-N), 658 (C-Cl), 632 (C-
S); 1H-NMR (CDCl
3
, 400 MHz): δ (ppm) 7.86 (d, J = 
8.4 Hz, 2H, H-2” & H-6”), 7.49 (d, J = 8.4 Hz, 2H, H-3” 
& H-5”), 3.66-3.63 (m, 2H, He-2’ & He-6’), 3.20 (q, J = 
7.6 Hz, 2H, H-1”’), 2.93-2.85 (m, 1H, H-4’), 2.62 (dt, J 
= 12.4, 2.8 Hz, 2H, Ha-2’ & Ha-6’), 2.14-2.09 (m, 2H, 
He-3’ & He-5’), 2.01-1.94 (m, 2H, Ha-3’ & Ha-5’), 1.43 (t, 
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5-{1-[(4-Chlorophenyl)sulfonyl]piperidin-4-yl}-
2-[(1-propyl)thio]-1,3,4-oxadiazole (7c)
White amorphous solid; Yield: 85 %; M.P.: 111-










; Mol. weight: 
401 gmol-1; IR (KBr, υmax, cm
-1): 3130 (Ar C-H), 1682 
(C=N), 1565 (Ar C=C), 1520 (N=O), 1386 (S=O), 
1228, 1026 (C-O-C), 1158 (C-N), 678 (C-Cl), 612 (C-
S); 1H-NMR (CDCl
3
, 400 MHz): δ (ppm) 7.67 (d, J 
= 8.4 Hz, 2H, H-2” & H-6”), 7.51 (d, J = 8.8 Hz, 2H, 
H-3” & H-5”), 3.70-3.67 (m, 2H, He-2’ & He-6’), 3.18 
(t, J = 7.2 Hz, 2H, H-1”’), 2.71-2.67 (m, 1H, H-4’), 2.56 
(dt, J = 12.0, 2.4 Hz, 2H, Ha-2’ & Ha-6’), 2.13-2.09 (m, 
2H, He-3’ & He-5’), 1.92 (dq, J = 10.8, 3.6 Hz, 2H, Ha-
3’ & Ha-5’), 1.34 (sex, J = 7.2 Hz, 3H, H-2”’), 1.03 (t, 



































Off-white amorphous solid; Yield: 77 %; M.P.: 156-










; Mol. weight: 401 
gmol-1; IR (KBr, υmax, cm
-1): 3067 (Ar C-H), 1673 (C=N), 
1582 (Ar C=C), 1525 (N=O), 1476 (S=O), 1170, 1026 
(C-O-C), 1142 (C-N), 662 (C-Cl), 638 (C-S); 1H-NMR 
(CDCl
3
, 400 MHz): δ (ppm) 7.69 (d, J = 8.4 Hz, 2H, 
H-2” & H-6”), 7.51 (d, J = 8.4 Hz, 2H, H-3” & H-5”), 
3.85 (sep, J = 6.8 Hz, 1H, H-1”’), 3.71-3.64 (m, 2H, He-
2’ & He-6’), 2.72-2.65 (m, 1H, H-4’), 2.56 (dt, J = 12.0, 
2.4 Hz, 2H, Ha-2’ & Ha-6’), 2.13-2.09 (m, 2H, He-3’ & 
He-5’), 1.99-1.86 (m, 2H, Ha-3’ & Ha-5’), 1.45 (d, J = 6.8 



































White amorphous solid; Yield: 76 %; M.P.: 113-










; Mol. weight: 
415 gmol-1; IR (KBr, υmax, cm
-1): 3080 (Ar C-H), 1688 
(C=N), 1578 (Ar C=C), 1545 (N=O), 1456 (S=O), 
1235, 1019 (C-O-C), 1161 (C-N), 660 (C-Cl), 622 (C-S); 
1H-NMR (CDCl
3
, 400 MHz): δ (ppm) 7.68 (d, J = 8.4 
Hz, 2H, H-2” & H-6”), 7.50 (d, J = 8.4 Hz, 2H, H-3” & 
H-5”), 3.67-3.62 (m, 2H, He-2’ & He-6’), 3.19 (t, J = 7.6 
Hz, 2H, H-1”’), 2.89-2.84 (m, 1H, H-4’), 2.63 (dt, J = 
12.4, 2.8 Hz, 2H, Ha-2’ & Ha-6’), 2.14-2.10 (m, 2H, He-3’ 
& He-5’), 2.02-1.92 (m, 2H, Ha-3’ & Ha-5’), 1.74 (qui, J 
= 7.6 Hz, 2H, H-2”’), 1.44 (sex, J = 7.2 Hz, 2H, H-3”’), 
0.92 (t, J = 7.6 Hz, 3H, H-4”’); EI-MS (m/z): 417 [M+2]+, 







































White amorphous solid; Yield: 80 %; M.P.: 105-










; Mol. weight: 
415 gmol-1; IR (KBr, υmax, cm
-1): 3036 (Ar C-H), 1685 
(C=N), 1592 (Ar C=C), 1514 (N=O), 1465 (S=O), 
1225, 1022 (C-O-C), 1163 (C-N), 653 (C-Cl), 631 (C-S); 
1H-NMR (CDCl
3
, 400 MHz): δ (ppm) 7.70 (d, J = 8.4 
Hz, 2H, H-2” & H-6”), 7.52 (d, J = 8.4 Hz, 2H, H-3” 
& H-5”), 4.96-4.77 (m, 1H, H-1”’), 3.70-3.68 (m, 2H, 
He-2’ & He-6’), 2.70-2.68 (m, 1H, H-4’), 2.57 (dt, J = 
12.4, 2.8 Hz, 2H, Ha-2’ & Ha-6’), 2.13-2.10 (m, 2H, He-
3’ & He-5’), 2.01-1.96 (m, 2H, H-2”’), 1.97-1.87 (m, 2H, 
Ha-3’ & Ha-5’), 1.44 (d, J = 6.8 Hz, 3H, H-4”’), 1.01 (t, 








































White amorphous solid; Yield: 84 %; M.P.: 115-










; Mol. weight: 429 
gmol-1; IR (KBr, υmax, cm
-1): 3026 (Ar C-H), 1675 (C=N), 
1582 (Ar C=C), 1534 (N=O), 1445 (S=O), 1215, 1042 
(C-O-C), 1193 (C-N), 673 (C-Cl), 641 (C-S); 1H-NMR 
(CDCl
3
, 400 MHz): δ (ppm) 7.69 (d, J = 8.4 Hz, 2H, 
H-2” & H-6”), 7.51 (d, J = 8.4 Hz, 2H, H-3” & H-5”), 
3.66-3.63 (m, 2H, He-2’ & He-6’), 3.18 (t, J = 7.6 Hz, 2H, 
H-1”’), 2.89-2.84 (m, 1H, H-4’), 2.63 (dt, J = 12.4, 2.8 
Hz, 2H, Ha-2’ & Ha-6’), 2.14-2.10 (m, 2H, He-3’ & He-
5’), 2.02-1.95 (m, 2H, Ha-3’ & Ha-5’), 1.75 (qui, J = 7.6 
Hz, 2H, H-2”’), 1.41-1.29 (m, 4H, H-3”’ & H-4”’), 0.88 
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5-{1-[(4-Chlorophenyl)sulfonyl]piperidin-4-yl}-
2-[(2-pentyl)thio]-1,3,4-oxadiazole (7h)
White amorphous solid; Yield: 78 %; M.P.: 98-99 ºC; 










; Mol. weight: 429 gmol-1; 
 IR (KBr, υmax, cm
-1): 3126 (Ar C-H), 1685 (C=N), 
1682 (Ar C=C), 1530 (N=O), 1385 (S=O), 1225, 1031 
(C-O-C), 1143 (C-N), 773 (C-Cl), 631 (C-S); 1H-NMR 
(CDCl
3
, 400 MHz): δ (ppm) 7.70 (d, J = 8.4 Hz, 2H, H-2” 
& H-6”), 7.52 (d, J = 8.4 Hz, 2H, H-3” & H-5”), 4.95-
4.80 (m, 1H, H-1”’), 3.71-3.67 (m, 2H, He-2’ & He-6’), 
2.69-2.65 (m, 1H, H-4’), 2.57 (dt, J = 12.4, 2.8 Hz, 2H, 
Ha-2’ & Ha-6’), 2.13-2.10 (m, 2H, He-3’ & He-5’), 2.02-
1.97 (m, 2H, H-2”’), 1.97-1.87 (m, 2H, Ha-3’ & Ha-5’), 
1.75-1.61 (m, 2H, H-3”’), 1.45 (d, J = 7.2 Hz, 3H, H-5”’), 
0.92 (t, J = 7.2 Hz, 3H, H-4”’); EI-MS (m/z): 431 [M+2]+, 







































Off-white amorphous solid; Yield: 75 %; M.P.: 123-










; Mol. weight: 
457 gmol-1; IR (KBr, υmax, cm
-1): 3122 (Ar C-H), 1682 
(C=N), 1688 (Ar C=C), 1538 (N=O), 1382 (S=O), 
1228, 1036 (C-O-C), 1148 (C-N), 772 (C-Cl), 633 (C-
S); 1H-NMR (CDCl
3
, 400 MHz): δ (ppm) 7.68 (d, J 
= 8.4 Hz, 2H, H-2” & H-6”), 7.49 (d, J = 8.4 Hz, 2H, 
H-3” & H-5”), 3.67-3.62 (m, 2H, He-2’ & He-6’), 3.18 
(t, J = 7.2 Hz, 2H, H-1”’), 2.89-2.84 (m, 1H, H-4’), 2.63 
(dt, J = 12.4, 2.8 Hz, 2H, Ha-2’ & Ha-6’), 2.14-2.10 (m, 
2H, He-3’ & He-5’), 2.02-1.95 (m, 2H, Ha-3’ & Ha-5’), 
1.76 (qui, J = 7.2 Hz, 2H, H-2”’), 1.40 (qui, J = 7.6 Hz, 
2H, H-3”’), 1.31-1.26 (m, 6H, H-4”’ to H-6”’), 0.85 (t, 








































Off-white amorphous solid; Yield: 86 %; M.P.: 











weight: 471 gmol-1; IR (KBr, υmax, cm
-1): 3129 (Ar C-H), 
1688 (C=N), 1680 (Ar C=C), 1540 (N=O), 1389 (S=O), 
1238, 1038 (C-O-C), 1138 (C-N), 782 (C-Cl), 639 (C-S); 
1H-NMR (CDCl
3
, 400 MHz): δ (ppm) 7.68 (d, J = 8.4 
Hz, 2H, H-2” & H-6”), 7.49 (d, J = 8.4 Hz, 2H, H-3” & 
H-5”), 3.66-3.63 (m, 2H, He-2’ & He-6’), 3.18 (t, J = 7.6 
Hz, 2H, H-1”’), 2.89-2.84 (m, 1H, H-4’), 2.63 (dt, J = 
12.4, 2.8 Hz, 2H, Ha-2’ & Ha-6’), 2.14-2.09 (m, 2H, He-
3’ & He-5’), 2.02-1.93 (m, 2H, Ha-3’ & Ha-5’), 1.75 (qui, 
J = 7.2 Hz, 2H, H-2”’), 1.40 (qui, J = 7.6 Hz, 2H, H-3”’), 
1.27-1.24 (m, 8H, H-4”’ to H-7”’), 0.85 (t, J = 6.8 Hz, 
3H, H-8”’); 13C-NMR (CDCl
3
, 100 MHz): δ (ppm) 168.3 
(C-5), 164.9 (C-2), 139.5 (C-1”), 134.8 (C-4”), 129.5 (C-
3” & C-5”), 129.0 (C-2” & C-6”), 45.0 (C-2’ & C-6’), 
32.5 (C-6”’), 32.2 (C-4’), 31.7 (C-5”’), 29.1 (C-4”’), 29.0 
(C-3”’), 28.9 (C-2”’), 28.5 (C-1”’), 28.3 (C-3’ & C-5’), 
22.6 (C-7”’), 14.0 (C-8”’); EI-MS (m/z): 473 [M+2]+, 







































Off-white amorphous solid; Yield: 76 %; M.P.: 131-










; Mol. weight: 429 
gmol-1; IR (KBr, υmax, cm
-1): 3134 (Ar C-H), 1673 (C=N), 
1610 (Ar C=C), 1524 (N=O), 1323 (S=O), 1228, 1012 
(C-O-C), 1148 (C-N), 761 (C-Cl), 624 (C-S); 1H-NMR 
(CDCl
3
, 400 MHz): δ (ppm) 7.68 (d, J = 8.8 Hz, 2H, 
H-2” & H-6”), 7.50 (d, J = 8.4 Hz, 2H, H-3” & H-5”), 
7.37 (br.d, J = 6.4 Hz, 2H, H-2”’ & H-6”’), 7.30-7.28 (m, 
3H, H-3”’ to H-5”’), 4.04 (s, 2H, H-7”’), 3.64-3.61 (m, 
2H, He-2’ & He-6’), 2.88-2.83 (m, 1H, H-4’), 2.62 (dt, 
J = 12.4, 2.8 Hz, 2H, Ha-2’ & Ha-6’), 2.12-2.08 (m, 2H, 
He-3’ & He-5’), 2.00-1.93 (m, 2H, Ha-3’ & Ha-5’); EI-











































White amorphous solid; Yield: 77 %; M.P.: 125-










; Mol. weight: 
463 gmol-1; IR (KBr, υmax, cm
-1): 3138 (Ar C-H), 1676 
(C=N), 1618 (Ar C=C), 1525 (N=O), 1327 (S=O), 
1224, 1017 (C-O-C), 1142 (C-N), 769 (C-Cl), 628 (C-
S); 1H-NMR (CDCl
3
, 400 MHz): δ (ppm) 7.68 (d, J 
= 8.4 Hz, 2H, H-2” & H-6”), 7.50 (d, J = 8.4 Hz, 2H, 
H-3” & H-5”), 7.32 (d, J = 7.6 Hz, 1H, H-6”’), 7.20-7.12 
(m, 3H, H-3”’ to H-5”’), 4.44 (s, 2H, H-7”’), 3.66-3.63 
Biological activity of synthesized 5-{1-[(4-chlorophenyl)sulfonyl]piperidin-4-yl}-2-mercapto-1,3,4-oxadiazole derivatives demonstrated by in silico
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(m, 2H, He-2’ & He-6’), 2.89-2.84 (m, 1H, H-4’), 2.63 
(dt, J = 12.4, 2.8 Hz, 2H, Ha-2’ & Ha-6’), 2.13-2.09 (m, 
2H, He-3’ & He-5’), 2.01-1.94 (m, 2H, Ha-3’ & Ha-5’), 
2.39 (s, 3H, CH
3























































; Mol. weight: 467 gmol-1; 
IR (KBr, υmax, cm
-1): 3137 (Ar C-H), 1672 (C=N), 1619 (Ar 
C=C), 1522 (N=O), 1326 (S=O), 1227, 1013 (C-O-C), 
1147 (C-N), 1056 (C-F), 720 (C-Cl), 626 (C-S); 1H-NMR 
(CDCl
3
, 400 MHz): δ (ppm) 7.68 (d, J = 8.4 Hz, 2H, H-2” 





 = 8.8, 5.6 Hz, 2H
b





 = 8.8 Hz, 2H
a
, H-3”’ & H-5”’), 4.38 
(s, 2H, H-7”’), 3.66-3.62 (m, 2H, He-2’ & He-6’), 2.88-
2.83 (m, 1H, H-4’), 2.62 (dt, J = 12.4, 2.8 Hz, 2H, Ha-2’ 
& Ha-6’), 2.12-2.08 (m, 2H, He-3’ & He-5’), 1.97-1.93 


























































; Mol. weight: 483 gmol-1; 
IR (KBr, υmax, cm
-1): 3127 (Ar C-H), 1682 (C=N), 
1609 (Ar C=C), 1532 (N=O), 1396 (S=O), 1237, 1023 
(C-O-C), 1167 (C-N), 780 (C-Cl), 646 (C-S); 1H-NMR 
(CDCl
3
, 400 MHz): δ (ppm) 7.68 (d, J = 8.8 Hz, 2H, 
H-2” & H-6”), 7.49 (d, J = 8.4 Hz, 2H, H-3” & H-5”), 
7.53 (dd, J = 7.2, 1.2 Hz, 1H, H-6”’), 7.38 (dd, J = 8.0, 0.8 
Hz, 1H, H-3”’), 7.23-7.19 (m, 2H, H-4”’ & H-5”’), 4.51 
(s, 2H, H-7”’), 3.65-3.62 (m, 2H, He-2’ & He-6’), 2.87-
2.82 (m, 1H, H-4’), 2.62 (dt, J = 12.4, 2.8 Hz, 2H, Ha-2’ 
& Ha-6’), 2.12-2.08 (m, 2H, He-3’ & He-5’), 2.00-1.91 
(m, 2H, Ha-3’ & Ha-5’); 
13C-NMR (CDCl
3
, 100 MHz): δ 
(ppm) 168.7 (C-5), 164.1 (C-2), 139.5 (C-1”), 134.8 (C-
4”), 134.4 (C-1”’), 133.6 (C-2”’), 131.4 (C-4”’), 129.7 
(C-5”’), 129.6 (C-3”’), 129.5 (C-3” & C-5”), 128.9 (C-
2” & C-6”), 127.0 (C-6”’), 44.9 (C-2’ & C-6’), 34.5 (C-
7”’), 32.2 (C-4’), 28.2 (C-3’ & C-5’); EI-MS (m/z): 487 
























































; Mol. weight: 483 gmol-1; 
IR (KBr, υmax, cm
-1): 3122 (Ar C-H), 1680 (C=N), 
1600 (Ar C=C), 1538 (N=O), 1398 (S=O), 1239, 1026 
(C-O-C), 1168 (C-N), 782 (C-Cl), 643 (C-S); 1H-NMR 
(CDCl
3
, 400 MHz): δ (ppm) 7.68 (d, J = 8.4 Hz, 2H, H-2” 
& H-6”), 7.49 (d, J = 8.4 Hz, 2H, H-3” & H-5”), 7.37 (s, 
1H, H-2”’), 7.29-7.23 (m, 3H, H-4”’ to H-6”’), 4.36 (s, 
2H, H-7”’), 3.66-3.63 (m, 2H, He-2’ & He-6’), 2.87-2.83 
(m, 1H, H-4’), 2.62 (dt, J = 12.0, 2.4 Hz, 2H, Ha-2’ & Ha-
6’), 2.12-2.08 (m, 2H, He-3’ & He-5’), 1.97-1.93 (m, 2H, 
Ha-3’ & Ha-5’); EI-MS (m/z): 487 [M+4]
+, 485 [M+2]+, 
























































; Mol. weight: 483 gmol-1; 
IR (KBr, υmax, cm
-1): 3125 (Ar C-H), 1683 (C=N), 
1608 (Ar C=C), 1534 (N=O), 1392 (S=O), 1230, 1028 
(C-O-C), 1166 (C-N), 780 (C-Cl), 642 (C-S); 1H-NMR 
(CDCl
3
, 400 MHz): δ (ppm) 7.67 (d, J = 8.4 Hz, 2H, 
H-2” & H-6”), 7.48 (d, J = 8.8 Hz, 2H, H-3” & H-5”), 
7.35 (d, J = 8.4 Hz, 2H, H-2”’ & H-6”’), 7.28 (d, J = 
8.4 Hz, 2H, H-3”’ & H-5”’), 4.37 (s, 2H, H-7”’), 3.67-
3.62 (m, 2H, He-2’ & He-6’), 2.87-2.81 (m, 1H, H-4’), 
2.61 (dt, J = 12.4, 2.8 Hz, 2H, Ha-2’ & Ha-6’), 2.13-
2.08 (m, 2H, He-3’ & He-5’), 1.99-1.93 (m, 2H, Ha-3’ 
& Ha-5’); EI-MS (m/z): 487 [M+4]












































White amorphous solid; Yield: 84 %; M.P.: 118-










; Mol. weight: 
526 gmol-1; IR (KBr, υmax, cm
-1): 3125 (Ar C-H), 1683 
Javed Iqbal, Aziz-ur-Rehman, Muhammad Athar Abbasi, Sabahat Zahra Siddiqui, Shahid Rasool, Muhammad Ashraf, 
Ambar Iqbal, Sujhla Hamid, Tahir Ali Chohan, Hira Khalid, Sabina Jhaumeer Laulloo, Syed Adnan Ali Shah
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(C=N), 1602 (Ar C=C), 1534 (N=O), 1390 (S=O), 1231, 
1023 (C-O-C), 1169 (C-N), 782 (C-Cl), 647 (C-S), 625 
(C-Br); 1H-NMR (CDCl
3
, 400 MHz): δ (ppm) 7.68 (d, 
J = 8.4 Hz, 2H, H-2” & H-6”), 7.55 (d, J = 8.0 Hz, 1H, 
H-3”’), 7.49 (d, J = 8.4 Hz, 2H, H-3” & H-5”), 7.25-7.21 
(m, 2H, H-5”’ & H-6”’), 7.14 (dt, J = 7.6, 1.2 Hz, 1H, 
H-4”’), 4.52 (s, 2H, H-7”’), 3.65-3.62 (m, 2H, He-2’ & 
He-6’), 2.87-2.82 (m, 1H, H-4’), 2.62 (dt, J = 12.4, 2.8 
Hz, 2H, Ha-2’ & Ha-6’), 2.12-2.08 (m, 2H, He-3’ & He-
5’), 1.99-1.90 (m, 2H, Ha-3’ & Ha-5’); EI-MS (m/z): 530 











































White amorphous solid; Yield: 83 %; M.P.: 173-










; Mol. weight: 
526 gmol-1; IR (KBr, υmax, cm
-1): 3128 (Ar C-H), 1688 
(C=N), 1605 (Ar C=C), 1539 (N=O), 1393 (S=O), 
1234, 1027 (C-O-C), 1166 (C-N), 722 (C-Cl), 649 (C-
S), 629 (C-Br); 1H-NMR (CDCl
3
, 400 MHz): δ (ppm) 
7.67 (d, J = 8.4 Hz, 2H, H-2” & H-6”), 7.48 (d, J = 8.8 
Hz, 2H, H-3” & H-5”), 7.43 (d, J = 8.0 Hz, 2H, H-2”’ & 
H-6”’), 7.28 (d, J = 8.4 Hz, 2H, H-3”’ & H-5”’), 4.35 (s, 
2H, H-7”’), 3.67-3.62 (m, 2H, He-2’ & He-6’), 2.87-2.81 
(m, 1H, H-4’), 2.61 (dt, J = 12.4, 2.8 Hz, 2H, Ha-2’ & Ha-
6’), 2.13-2.08 (m, 2H, He-3’ & He-5’), 1.99-1.93 (m, 2H, 
Ha-3’ & Ha-5’); EI-MS (m/z): 530 [M+4]
+, 528 [M+2]+, 











































Off-white amorphous solid; Yield: 82 %; M.P.: 108-










; Mol. weight: 463 
gmol-1; IR (KBr, υmax, cm
-1): 3155 (Ar C-H), 1643 (C=N), 
1592 (Ar C=C), 1544 (N=O), 1450 (S=O), 1241, 1033 
(C-O-C), 1182 (C-N), 680 (C-Cl), 624 (C-S); 1H-NMR 
(CDCl
3
, 400 MHz): δ (ppm) 7.68 (d, J = 8.4 Hz, 2H, 
H-2” & H-6”), 7.49 (d, J = 8.4 Hz, 2H, H-3” & H-5”), 
7.28 (d, J = 7.2 Hz, 2H, H-2”’ & H-6”’), 7.23-7.20 (m, 
3H, H-3”’ to H-5”’), 3.66-3.63 (m, 2H, He-2’ & He-6’), 
3.43 (t, J = 7.6 Hz, 2H, H-8”’), 3.08 (t, J = 7.6 Hz, 2H, 
H-7”’), 2.89-2.84 (m, 1H, H-4’), 2.66-2.61 (m, 2H, Ha-2’ 
& Ha-6’), 2.14-2.10 (m, 2H, He-3’ & He-5’), 2.00-1.95 





















































White amorphous solid; Yield: 80 %; M.P.: 116-117 










; Mol. weight: 477 gmol-
1; IR (KBr, υmax, cm
-1): 3152 (Ar C-H), 1642 (C=N), 1590 
(Ar C=C), 1542 (N=O), 1452 (S=O), 1244, 1032 (C-O-C), 
1180 (C-N), 684 (C-Cl), 626 (C-S); 1H-NMR (CDCl
3
, 300 
MHz): δ (ppm) 7.69 (d, J = 8.4 Hz, 2H, H-2” & H-6”), 7.49 
(d, J = 8.4 Hz, 2H, H-3” & H-5”), 7.29-7.15 (m, 5H, H-2”’ 
to H-6”’), 3.66-3.63 (m, 2H, He-2’ & He-6’), 3.20 (t, J = 7.2 
Hz, 2H, H-9”’), 2.89-2.84 (m, 1H, H-4’), 2.75 (t, J = 7.5 Hz, 
2H, H-7”’), 2.66-2.61 (m, 2H, Ha-2’ & Ha-6’), 2.16-2.12 (m, 
2H, He-3’ & He-5’), 2.11 (qui, J = 7.2 Hz, 2H, H-8”’), 2.00-
1.95 (m, 2H, Ha-3’ & Ha-5’); EI-MS (m/z): 479 [M+2]
+, 























































White amorphous solid; Yield: 74 %; M.P.: 122-










; Mol. weight: 494 
gmol-1; IR (KBr, υmax, cm
-1): 3157 (Ar C-H), 1645 (C=N), 
1592 (Ar C=C), 1548 (N=O), 1457 (S=O), 1246, 1038 
(C-O-C), 1183 (C-N), 689 (C-Cl), 623 (C-S); 1H-NMR 
(CDCl
3
, 400 MHz): δ (ppm) 8.26 (s, 1H, H-2”’), 8.13 (d, 
J = 8.4 Hz, 1H, H-4”’), 7.78 (d, J = 7.6 Hz, 1H, H-6”’), 
7.68 (d, J = 8.8 Hz, 2H, H-2” & H-6”), 7.49 (d, J = 8.0 Hz, 
2H, H-3” & H-5”), 7.47 (t, J = 7.2 Hz, 1H, H-5”’), 4.47 
(s, 2H, H-7”’), 3.68-3.65 (m, 2H, He-2’ & He-6’), 2.88-
2.82 (m, 1H, H-4’), 2.59 (dt, J = 12.0, 2.8 Hz, 2H, Ha-2’ 
& Ha-6’), 2.13-2.08 (m, 2H, He-3’ & He-5’), 1.98-1.90 















































Off-white amorphous solid; Yield: 79 %; M.P.: 166-










; Mol. weight: 494 
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gmol-1; IR (KBr, υmax, cm
-1): 3156 (Ar C-H), 1648 (C=N), 
1594 (Ar C=C), 1546 (N=O), 1458 (S=O), 1242, 1034 
(C-O-C), 1187 (C-N), 680 (C-Cl), 625 (C-S); 1H-NMR 
(CDCl
3
, 400 MHz): δ (ppm) 7.81 (d, J = 7.6 Hz, 1H, H-3”’ 
& H-5”’), 7.68 (d, J = 8.8 Hz, 2H, H-2” & H-6”), 7.64 (t, J 
= 7.6 Hz, 1H, H-2”’ & H-6”’), 7.49 (d, J = 8.0 Hz, 2H, H-3” 
& H-5”), 4.46 (s, 2H, H-7”’), 3.69-3.65 (m, 2H, He-2’ & 
He-6’), 2.86-2.81 (m, 1H, H-4’), 2.61 (dt, J = 12.0, 2.4 Hz, 
2H, Ha-2’ & Ha-6’), 2.14-2.09 (m, 2H, He-3’ & He-5’), 1.97-
1.92 (m, 2H, Ha-3’ & Ha-5’); EI-MS (m/z): 496 [M+2]
+, 













































White amorphous solid; Yield: 78 %; M.P.: 211-212 










; Mol. weight: 513 
gmol-1; IR (KBr, υmax, cm
-1): 3150 (Ar C-H), 1640 (C=N), 
1598 (Ar C=C), 1541 (N=O), 1455 (S=O), 1247, 1039 
(C-O-C), 1188 (C-N), 690 (C-Cl), 627 (C-S); 1H-NMR 
(CDCl
3
, 400 MHz): δ (ppm) 7.68 (d, J = 8.0 Hz, 2H, H-2” 
& H-6”), 7.49 (d, J = 8.4 Hz, 2H, H-3” & H-5”), 3.81 (t, J = 
7.2 Hz, 2H, H-1”’), 3.71-3.65 (m, 2H, He-2’ & He-6’), 3.32 
(t, J = 7.2 Hz, 2H, H-2”’), 2.69-2.64 (m, 1H, H-4’), 2.57 
(dt, J = 12.0, 2.4 Hz, 2H, Ha-2’ & Ha-6’), 2.15-2.10 (m, 
2H, He-3’ & He-5’), 1.96-1.89 (m, 2H, Ha-3’ & Ha-5’); EI-







































White amorphous solid; Yield: 83 %; M.P.: 157-












; Mol. weight: 
421 gmol-1; IR (KBr, υmax, cm
-1): 3058 (Ar C-H), 1664 
(C=N), 1602 (Ar C=C), 1508 (N=O), 1385 (S=O), 
1178, 1030 (C-O-C), 1086 (C-N), 634 (C-Cl), 606 (C-S); 
1H-NMR (CDCl
3
, 400 MHz): δ (ppm) 7.66 (d, J = 8.4 
Hz, 2H, H-2” & H-6”), 7.51 (d, J = 8.4 Hz, 2H, H-3” & 
H-5”), 3.79 (t, J = 7.2 Hz, 2H, H-1”’), 3.72-3.67 (m, 2H, 
He-2’ & He-6’), 3.64 (t, J = 7.2 Hz, 2H, H-2”’), 2.73-
2.68 (m, 1H, H-4’), 2.56 (dt, J = 12.0, 2.4 Hz, 2H, Ha-2’ 
& Ha-6’), 2.14-2.08 (m, 2H, He-3’ & He-5’), 1.97-1.92 









































Off-white amorphous solid; Yield: 82 %; M.P.: 170-










; Mol. weight: 464 
gmol-1; IR (KBr, υmax, cm
-1): 3054 (Ar C-H), 1665 (C=N), 
1604 (Ar C=C), 1502 (N=O), 1382 (S=O), 1173, 1033 
(C-O-C), 1085 (C-N), 638 (C-Cl), 608 (C-S); 1H-NMR 
(CDCl
3
, 400 MHz): δ (ppm) 7.67 (d, J = 8.0 Hz, 2H, H-2” 
& H-6”), 7.49 (d, J = 8.0 Hz, 2H, H-3” & H-5”), 3.71 (t, 
J = 7.2 Hz, 2H, H-1”’), 3.70-3.64 (m, 2H, He-2’ & He-6’), 
3.62 (t, J = 7.2 Hz, 2H, H-2”’), 2.70-2.66 (m, 1H, H-4’), 
2.57 (dt, J = 12.4, 2.0 Hz, 2H, Ha-2’ & Ha-6’), 2.14-2.09 
(m, 2H, He-3’ & He-5’), 1.95-1.87 (m, 2H, Ha-3’ & Ha-5’); 







































Light-bluish amorphous solid; Yield: 82 %; M.P.: 










; Mol. weight: 
445 gmol-1; IR (KBr, υmax, cm
-1): 3056 (Ar C-H), 1667 
(C=N), 1608 (Ar C=C), 1504 (N=O), 1387 (S=O), 
1175, 1032 (C-O-C), 1080 (C-N), 636 (C-Cl), 602 (C-S); 
1H-NMR (CDCl
3
, 400 MHz): δ (ppm) 7.68 (d, J = 8.4 Hz, 
2H, H-2” & H-6”), 7.49 (d, J = 8.4 Hz, 2H, H-3” & H-5”), 
5.24 (t, J = 4.0 Hz, 1H, H-2”’), 4.01-3.98 (m, 2H, He-4”’ 
& He-5”’), 3.90-3.86 (m, 2H, Ha-4”’ & Ha-5”’), 3.65-3.61 
(m, 2H, He-2’ & He-6’), 3.44 (d, J = 4.0 Hz, 2H, H-6”’), 
2.90-2.85 (m, 1H, H-4’), 2.65 (dt, J = 12.4, 2.8 Hz, 2H, 
Ha-2’ & Ha-6’), 2.14-2.09 (m, 2H, He-3’ & He-5’), 2.02-
1.95 (m, 2H, Ha-3’ & Ha-5’); EI-MS (m/z): 447 [M+2]
+, 








































The different S-substituted derivatives, 7a-z, of 
5-{1-[(4-chlorophenyl)sulfonyl]piperidin-4-yl}-2-
mercapto-1,3,4-oxadiazole (5) were synthesized by the 
protocol outlined in Figure 1. The different alkyl/aralkyl 
groups are listed in Table I. The bioactivity analysis 
included antibacterial activity against gram-positive 
Javed Iqbal, Aziz-ur-Rehman, Muhammad Athar Abbasi, Sabahat Zahra Siddiqui, Shahid Rasool, Muhammad Ashraf, 
Ambar Iqbal, Sujhla Hamid, Tahir Ali Chohan, Hira Khalid, Sabina Jhaumeer Laulloo, Syed Adnan Ali Shah
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and gram-negative bacteria, and inhibitory activity 
against AChE and urease enzymes. Computational 
and BSA binding studies were also carried out to see 
the interaction of synthesized compounds with amino 
acid residues and binding capacity with this specific 
protein, respectively.
FIGURE 1 - Synthesis of 5-{1-[(4-chlorophenyl)sulfonyl]piperidin-4-yl}-2-[(alkyl/aralkyl)thio]-1,3,4-oxadiazole (7a-z).
TABLE I - Different alkyl/aralkyl groups
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TABLE I - Different alkyl/aralkyl groups
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Compound 7n is selected for single compound 
discussion. It was obtained as a white amorphous 
solid. The % yield was 81 %, and the melting point was 













, and molecular mass, 483 gmol-1, 
were established through 1H-NMR and EI-MS spectra. 
The IR spectrum showed absorptions for the main 
functionalities present in the molecule, namely 3127 
(Ar C-H), 1682 (C=N), 1609 (Ar C=C), 1532 (N=O), 
1396 (S=O), 1237, 1023 (C-O-C), 1167 (C-N), 710 
(C-Cl) and 646 (C-S). The mass spectrum displayed 
different fragments that confirmed the molecular 
structure of all the synthesized compounds. The 
fragments at m/z 286 and 284 demonstrated the partial 
cleavage of the 1,3,4-oxadiazole ring. The fragment 
at m/z 175 was assigned to the 4-chlorophenylsulfonyl 
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group and that at m/z 111 to the 4-chlorophenyl group. 
All these fragments were shown by all the compounds. 
The compound 7n specifically showed two fragments 
at m/z 125 and 65 for 2-chlorobenzyl as substituted 
tropyllium cation and cyclopentadienyl cation, 
respectively. The other prominent fragments are given 
in Figure 2. The two doublets of 1H-NMR signals at 
δ 7.68 (d, J = 8.8 Hz, 2H, H-2” & H-6”) and 7.49 (d, 
J = 8.4 Hz, 2H, H-3” & H-5”) were assigned to the 
4-chlorophenylsulfonyl moiety; five signals at δ 3.65-
3.62 (m, 2H, He-2’ & He-6’), 2.87-2.82 (m, 1H, H-4’), 
2.62 (dt, J = 12.4, 2.8 Hz, 2H, Ha-2’ & Ha-6’), 2.12-2.08 
(m, 2H, He-3’ & He-5’) and 2.00-1.91 (m, 2H, Ha-3’ & 
Ha-5’) were assigned to the piperidine moiety; and the 
signals at δ 7.53 (dd, J = 7.2, 1.2 Hz, 1H, H-6”’), 7.38 
(dd, J = 8.0, 0.8 Hz, 1H, H-3”’), 7.23-7.19 (m, 2H, H-4”’ 
& H-5”’) and 4.51 (s, 2H, H-7”’) were assigned to the 
2-chlorobenzyl group. 13C-NMR also corroborated 
the carbon skeleton of the molecule by exhibiting the 
following signals: six at δ (ppm) 168.7 (C-5), 164.1 (C-
2), 139.5 (C-1”), 134.8 (C-4”), 134.4 (C-1”’) and 133.6 
(C-2”’) for six quaternary carbons; seven at δ (ppm) 
131.4 (C-4”’), 129.7 (C-5”’), 129.6 (C-3”’), 129.5 (C-3” 
& C-5”), 128.9 (C-2” & C-6”), 127.0 (C-6”’) and 32.2 
(C-4’) for nine methine carbons; and three at δ (ppm) 
44.9 (C-2’ & C-6’), 34.5 (C-7”’) and 28.2 (C-3’ & 
C-5’) for five methylene carbons. On the basis of these 
spectral data, the structure of 7n was determined to 
be 5-{1-[(4-chlorophenyl)sulfonyl]piperidin-4-yl}-
2-[(2-chlorobenzyl)thio]-1,3,4-oxadiazole. Likewise, 
the structures of other synthesized compounds were 
corroborated through spectral data.
FIGURE 2 - Proposed mass fragmentation pattern of 5-{1-[(4-chlorophenyl)sulfonyl]piperidin-4-yl}-2-[(2-chlorobenzyl)thio]-
1,3,4-oxadiazole (7n).
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Antibacterial activity (in vitro)
Antibacterial activity was evaluated for all 
the compounds and the results are interpreted as 
% inhibition and MIC in Table II and Table III, 
respectively. The reference drug was ciprofloxacin. 
The results demonstrated slightly moderate to strong 
antibacterial potential of the synthesized compounds 
against S. typhi and B. subtilis and weakly moderate 
against the other three bacterial strains. Against S. 
typhi, 7q, 7t, 7u, 7w and 7z were the most active 
compounds with MIC values of 9.23±1.34, 9.22±3.28, 
9.51±4.91, 8.78±2.50 and 8.23±3.00 µM, respectively. 
The high activity of these compounds was attributed 
to the presence of the 2-bromobenzyl, 3-phenylpropyl, 
3-nitrobenzyl, 2-iodoethyl and 1,3-dioxalan-2-ylmethyl 
groups, respectively. The reference drug, ciprofloxacin, 
showed a MIC value of 7.15±1.29 µM. The most active 
compound was 7z, bearing three heterocyclic rings in 
its structure. The other molecules were also found to be 
moderately effective growth inhibitors of this bacterial 
strain. The growth of the bacterial strain E. coli was 
inhibited by almost all the compounds but to a very 
low extent, although some were moderate inhibitors. 
The most active compound against this strain was 7b, 
bearing an ethyl group, and exhibited a MIC value of 
10.32±3.65 µM compared to the reference at 7.90±1.87 
µM. Two compounds, 7p and 7v, were inactive against 
this strain. Likewise, P. aeruginosa and S. aureus 
were inhibited by all the compounds but to a weak to 
moderate level. The most active compound against both 
of the strains was 7u, bearing a 3-nitrobenzyl group, and 
showed a MIC value of 10.40±1.67 and 10.58±1.82 µM 
compared to the reference at 8.21±1.21 and 8.00±2.98 
µM for P. aeruginosa and S. aureus, respectively. 
Compound 7p was inactive against both strains, 
while 7v and 7y were also inactive against S. aureus. 
The compounds displayed moderate to strong activity 
against B. subtilis. The compounds 7m, 7n, 7s and 7t 
were the most active ones with MIC values of 9.28±4.43, 
8.95±1.93, 9.70±2.21 and 9.25±1.43 µM compared to 
that of the reference drug, i.e., 7.12±2.11 µM. The better 
activities of these compounds might have been due to 
the presence of the 4-fluorobenzyl, 2-chlorobenzyl, 
2-phenylethyl and 3-phenylpropyl groups, respectively. 
Overall, the halogenated groups attached to sulfur 
of 1,3,4-oxadiazole, boosted considerably bioactive 
potential. No doubt, the antibacterial potential was 
already increased by the 4-chlorophenyl group present 
in all the synthesized molecules. The size and position 
of halogens in the molecule have a considerable effect 
on biological activities (Liu et al., 2012).
TABLE II - The % inhibition for antibacterial activity of synthesized compounds
Compounds
% INHIBITION
S. typhi (-) E. coli (-) P. aeruginosa (-) S. aureus (+) B. subtilis (+)
7a 75.59±0.32 60.79±0.42 62.60±1.99 59.05±1.95 76.92±1.57
7b 73.23±1.86 61.25±0.42 58.06±0.92 57.05±4.05 78.43±1.06
7c 71.00±0.91 67.78±5.00 68.37±0.05 64.85±0.55 77.17±0.40
7d 76.18±1.18 65.23±1.62 68.98±1.02 60.40±2.80 79.80±1.92
7e 63.95±2.77 62.08±2.18 58.88±0.71 56.85±1.65 63.69±4.70
7f 72.77±0.59 64.58±0.88 66.68±0.87 56.65±2.75 72.78±2.37
7g 67.64±1.73 63.06±1.30 63.06±1.22 60.90±1.60 65.30±4.49
7h 70.05±2.14 60.09±1.57 61.07±2.70 55.35±2.85 73.23±0.30
(continuing)
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TABLE II - The % inhibition for antibacterial activity of synthesized compounds
Compounds
% INHIBITION
S. typhi (-) E. coli (-) P. aeruginosa (-) S. aureus (+) B. subtilis (+)
7i 63.95±1.23 55.69±0.42 55.87±0.50 51.45±1.45 65.56±4.49
7j 62.68±0.77 54.58±0.79 55.56±3.32 53.05±1.05 61.01±1.62
7k 70.68±0.32 62.18±0.14 63.72±0.36 55.75±1.15 72.17±2.07
7l 76.27±1.00 66.90±1.25 66.58±1.28 64.30±1.50 62.47±2.88
7m 63.55±2.45 55.56±2.87 51.53±4.69 50.45±2.75 67.58±5.00
7n 73.59±0.50 61.62±0.97 65.26±1.28 56.75±4.75 75.20±1.57
7o 66.64±0.18 57.96±1.57 61.28±1.79 60.70±2.70 66.52±5.00
7p 58.50±2.05 39.68±5.00 47.14±3.47 35.75±1.85 56.62±3.99
7q 74.59±0.41 61.39±1.02 63.57±0.41 58.90±2.70 76.57±0.61
7r 63.50±1.77 60.23±1.81 62.14±0.41 57.95±0.95 65.71±2.17
7s 68.91±1.36 62.64±1.69 67.81±1.07 61.95±0.75 68.69±0.20
7t 72.05±2.23 66.30±0.56 69.29±0.20 62.80±1.00 74.19±2.27
7u 72.95±1.05 63.61±1.11 66.07±1.17 62.90±0.60 68.94±4.80
7v 52.86±0.68 47.78±1.94 50.56±3.93 43.45±1.25 57.88±4.75
7w 75.36±0.91 66.62±1.06 68.21±0.05 64.90±0.50 73.74±0.61
7x 61.32±1.14 54.49±0.05 58.27±2.35 56.25±3.25 66.01±3.79
7y 54.91±1.82 58.15±4.44 51.38±2.70 49.40±4.70 57.32±0.15
7z 79.14±0.32 57.31±5.00 60.82±4.69 51.45±4.05 75.05±0.40
Ciprofloxacin 91.79±1.45 90.87±0.56 92.13±0.97 90.45±2.98 91.18±1.22
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TABLE III - The MIC of antibacterial activity of synthesized compounds
Compounds
MIC (µM)
S. typhi (-) E. coli (-) P. aeruginosa (-) S. aureus (+) B. subtilis (+)
7a 12.51±2.41 13.77±1.73 14.90±4.50 13.85±1.22 11.92±2.14
7b 10.46±4.74 10.32±3.65 15.91±5.00 12.67±3.11 11.72±3.07
7c 13.07±5.00 12.60±4.23 12.84±1.42 11.12±3.78 10.66±2.93
7d 10.44±4.48 12.24±4.71 12.40±1.17 11.04±4.46 11.96±4.57
7e 15.67±5.00 14.55±4.52 15.31±1.42 13.17±2.50 12.99±1.14
7f 10.22±3.62 13.82±3.27 13.62±2.67 14.69±3.85 12.18±1.36
7g 12.75±2.59 15.37±3.65 12.86±3.08 11.86±5.00 13.26±4.71
7h 13.40±1.03 15.41±0.77 15.00±1.08 17.14±5.00 16.02±3.21
7i 12.53±1.98 17.29±0.58 16.16±2.92 17.75±1.21 12.18±2.64
7j 14.49±2.24 18.31±0.10 17.95±2.17 16.50±1.22 12.41±1.17
7k 11.78±5.00 13.14±2.31 13.55±4.25 11.84±1.95 11.52±4.57
7l 10.36±5.00 10.38±1.83 12.22±1.75 10.65±1.99 12.65±1.36
7m 12.48±3.97 17.10±0.19 19.03±1.50 17.83±5.00 9.28±4.43
7n 10.44±2.33 12.09±3.85 14.20±2.75 12.00±3.18 8.95±1.93
7o 11.68±1.95 15.63±4.33 15.56±2.50 14.25±3.72 11.04±3.36
7p 15.53±4.31 - - - 18.19±0.71
7q 9.23±1.34 14.86±1.58 14.73±2.08 11.44±1.22 10.79±2.29
7r 11.81±1.95 11.16±1.35 12.32±1.83 12.01±1.20 10.54±4.57
7s 10.86±4.91 11.20±1.96 12.54±1.92 10.91±0.74 9.70±2.21
7t 9.22±3.28 11.41±1.19 11.83±1.17 10.65±2.23 9.25±1.43
7u 9.51±4.91 10.68±1.10 10.40±1.67 10.58±1.82 10.63±2.79
7v 16.78±1.03 - 19.64±4.33 - 12.84±4.14
7w 8.78±2.50 10.38±2.60 10.68±2.50 10.62±1.50 11.39±5.00
(continuing)
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TABLE III - The MIC of antibacterial activity of synthesized compounds
Compounds
MIC (µM)
S. typhi (-) E. coli (-) P. aeruginosa (-) S. aureus (+) B. subtilis (+)
7x 15.86±1.60 18.60±2.79 16.99±0.58 15.60±1.35 13.10±4.36
7y 17.61±1.52 17.97±0.38 19.49±3.25 - 16.61±2.57
7z 8.23±3.00 11.20±1.35 11.56±2.67 18.83±3.99 10.78±4.71
Ciprofloxacin 7.15±1.29 7.90±1.87 8.21±1.21 8.00±2.98 7.12±2.11
AChE inhibition studies
All the synthesized compounds were tested for 
AChE inhibitory activity and the results (% inhibition 
and IC
50
) are given in Table IV. This activity nullifies 
the effects of AChE causing mental disorders. The main 
stream of the tested compounds was found active in 
the variable range from slightly active to highly active 
because of the collective effect of three heterocyclic 
moieties shown in the general synthetic scheme. 
Compounds 7m, 7n, 7q, 7s, 7t, 7x and 7y were the most 
active members of this series, acting as anti-AChE 
agents with IC
50
 values of 95.57±0.21, 72.24±0.18, 
52.23±0.23, 51.39±0.21, 65.91±0.23, 46.21±0.22 and 
83.56±0.17 µM, respectively, as compared to that of 
eserine used as a reference standard, i.e., 0.04±0.0001 
µM. The high activity of the above compounds might 
have been due to the presence of electron withdrawing-
species in the N-substituted aromatic ring shown in 
Table I. The compounds showing moderate potential 
against AChE were 7i, 7j, 7k, 7l, 7p, 7u and 7v with 
IC
50
 values of 133.25±0.15, 179.34±0.12, 185.42±0.17, 
139.81±0.22 and 189.64±0.19 µM, respectively. 
The presence of bulky groups in the N-substituted 
aromatic ring was responsible for moderate activity. 
The low activity of compounds 7e and 7f was due 
to the presence of electron-rich moieties in the 
N-substituted ring. Among the active members of 
this series, compounds 7q, 7s and 7x were the most 
active agents and could be recommended for in vivo 
studies. The highest inhibition potential of these 
highly active members could have been due to the 
2-bromobenzyl, 2-phenylethyl and 2-chloroehyl 
substituents, respectively.













7a 28.32±0.16 - 28.72±0.12 -
7b 37.95±0.18 - 32.43±0.17 -
7c 25.74±0.14 - 35.56±0.13
7d 23.45±0.17 - 98.14±0.11 23.58±0.02
(continuing)
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7e 67.34±0.26 397.51±0.19 34.83±0.16 -
7f 69.35±0.29 334.72±0.21 32.45±0.15 -
7g 44.52±0.22 - 25.87±0.14 -
7h 18.39±0.25 - 24.65±0.18 -
7i 84.34±0.29 129.25±0.18 24.76±0.12 -
7j 26.82±0.18 - 32.12±0.15 -
7k 82.62±0.26 179.34±0.18 35.24±0.13 -
7l 83.24±0.28 178.52±0.22 96.72±0.04 2.14±0.003
7m 91.52±0.29 95.57±0.16 98.13±0.02 0.63±0.001
7n 91.39±0.22 72.24±0.14 97.54±0.03 2.17±0.006
7o 84.27±0.28 139.81±0.19 97.16±0.05 1.13±0.003
7p 83.53±0.29 187.64±0.23 97.24±0.04 1.21±0.005
7q 90.65±0.21 47.23±0.16 29.75±0.13 -
7r 35.74±0.15 - 96.56±0.02 6.28±0.003
7s 90.73±0.24 51.39±0.17 32.81±0.13 -
7t 90.29±0.21 72.91±0.15 36.75±0.12 -
7u 83.63±0.29 183.72±0.21 97.62±0.04 2.39±0.005
7v 79.52±0.28 215.53±0.23 97.34±0.07 2.15±0.002
7w 18.22±0.14 - 14.11±0.12 -
7x 90.38±0.25 49.21±0.17 96.26±0.06 2.26±0.003
7y 90.52±0.26 83.56±0.16 97.54±0.03 2.14±0.002
7z 16.56±0.12 - 23.85±0.14 -
Eserine 91.27±1.17 0.04±0.0001 98.21±0.18 21.25±0.15
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Urease inhibition studies
All the synthesized compounds were tested for 
anti-urease activity with reference to thiourea used as 
the standard. The results showed that all the compounds 
had outstanding urease inhibitory activity with a few 
exceptions (Table IV). The compounds were even much 
more active compared to the standard used. Compounds 
7l, 7m, 7n, 7o, 7p, 7r, 7u, 7v, 7x and 7v were highly active 
against urease with IC
50
 values of 2.14±0.003, 0.63±0.001, 
2.17±0.006, 1.13±0.003, 1.21±0.005, 6.28±0.003, 
2.39±0.005, 2.15±0.002, 2.26±0.003 and 2.14±0.002 µM 
compared to thiourea with an IC
50
 value of 21.25±0.15 
µM. The high level of anti-urease activity might have 
been attributed to the presence of electron-withdrawing 
substituents (Table I), such as 7m with a 4-fluorobenzyl 
group, the most active compound of the series. All the 
tested compounds showed exceptional urease inhibitory 
potential and could be used to design new drugs to control 
the negative effects of urease after in vivo studies. 
Docking study for binding of 7x with AChE 
The 7x compound was used to evaluate its 
molecular docking in AChE inhibition studies. 7x 
showed the highest inhibitory potential against AChE. It 
was necessary to identify the active site present in the 
molecule, responsible for its best activity. To understand 
the possible factors responsible for its better activity, 
its docking studies were carried out. The Surflex-Dock 
module of SybylX-1.3 was used to dock ligand 7x into the 
active site of AChE enzyme (Figure 3). The authenticity 
reliability of our docking procedure was attained by the 
extraction of donepezil and re-docking into the active 
cite of AChE. The comparison of docked poses and 
experimentally determined binding mode was done 
by donepezil in AChE. Molecular docking results of 
ligand poses were overlapped with the crystallographic 
confirmation of donepezil in AChE, which showed the 
reliability of docking studies. The graphic analysis of 
docking results (Figure 3) demonstrated that ligand 7x 
penetrated deeply into the two main active sites of AChE 
(CAS and PAS). In the active site of AChE, the ligand 
acquired such a binding conformation, so that the nitrogen 
of the oxdiazole ring (B-ring) was able to form a H-bond 
with the backbone NH
2
 of Phe295 (Figure 3). The SO
2
 
group of 4-chlorobezene sulfonyl was also able to form 
a H-bond with NH
2 
groups of TYR337 and TRP86. The 
chlorine of the 4-chlorobezene sulfonyl group (A-ring) 
was shown to penetrate deeply into the CAS region where 
FIGURE 3 - Docked conformation of AChE inhibitors 7x (Cyan), 7x (Magenta) superimposed over experimental conformation 
of donepezil (Magenta) in AChE main binding site. 
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its Cl at C4 of ring-A could establish a hydrophobic or 
van der Waals interaction with surrounding residues 
Glu202, Ser203 and Gly120. The chlorine of the ethyl 
group substituted at the S position extended well near the 
solvent-exposed region where it could establish H-bonds 
with the backbone and side chain of the surrounding 
residue Phe295. The following variations in ligand-
receptor interaction pattern could account for the higher 
AChE inhibitory potency of compound 7x.
BSA binding studies using fluorescence measurements
Nitrogen-containing compounds are well known 
for their broad spectrum of biological applications. 
Oxadiazole and its derivatives are the class of compounds 
having such functionalities with various biological 
applications such as antibacterial, antispasmodic, 
anti-inflammatory, antiplatelet aggregation, tumor 
cell growth inhibition and differentiation, tumor cell 
apoptosis, etc. (Holt, Chaires, Trent, 2008). The current 
study was designed to determine the binding of the 
synthesized compounds to BSA to better understand 
their pharmacological effects. The selected synthesized 
compounds were used to evaluate the effects of different 
substituents on BSA binding capacity. The binding of 
these compounds was determined by fluorometric 
titrations of BSA with varying concentration of the 
derivatives (0 - 5.57 x 10-4 M). Their binding abilities and 
binding sites were compared to that of the fluorescence 
markers warfarin and ibuprofen. 
BSA shows a maximum emission at λ
em
 = 336 
nm. Addition of the synthesized compounds was found 
to quench the fluorescence intensity of BSA, showing 
that these derivatives were able to bind to BSA, causing 
some modification in the microenvironment around 
the amino acid residues situated in the sub-domain of 
BSA, leading to a hypochromic shift in the fluorescence 
spectrum. Fluorescence quenching can be classified 
as either a static or dynamic process and is caused by 
different mechanisms including excited state reactions, 
molecular rearrangements, energy transfer, formation of 
ground state complex and collisional quenching (Wang 
et al., 2013). The type of quenching mechanism is 
usually interpreted by the Stern-Volmer equation:
F
o
 / F = 1 + K
SV




 [Q] + 1 Equation 1
where F
o
 and F are the fluorescence intensities of BSA 
respectively before and after addition of quencher, 
K
sv
 is the Stern-Volmer quenching constant, [Q] is 
the concentration of the quencher, K
q
 is the apparent 
bimolecular quenching rate constant, τ
o
 is the average 
lifetime of the biomolecule without the quencher and its 
value is 10-8 s (Zhang et al., 2012). The emission spectra 
of the test compounds and their respective Stern-Volmer 
plots are given in Figure 4. 
In general, the calculated K
q
 values (Table V) 
were found to be larger than the maximum scattering 
collision quenching constant (2 × 1010 M-1 s−1) in dynamic 
quenching, which indicated that the fluorescence 
quenching process of BSA with the synthesized 
compounds, as well as warfarin and ibuprofen, were 
primarily governed by a static quenching mechanism 
(Wang et al., 2013), rather than a dynamic one. The 
binding constant K
a
 and the number of binding sites n 




 – F) / F] = log K
a
 + n log[Q] Equation 2
The double logarithm plots of the different 
compounds are shown in Figure 5 and their binding 
constant Ka is given in Table V. The presence of halogen 
atoms in (7o and 7m) was found to decrease the binding 
constant. However, compound 7u showed the strongest 
binding with BSA, which was due to the presence of a 
nitro group at the meta position, enhancing the binding 
of 7u to BSA. The strong binding of compound 7u to 
BSA may account for its high antibacterial potential.
CONCLUSION
The synthesized compounds with notable yields 
were structurally identified through spectral data. The 
interactions with amino acid residues as well as with 
specific proteins responsible for the pharmacological 
activity of the synthesized compounds were availed 
through docking and BSA binding interactions, 
respectively. The antibacterial activity results 
demonstrated moderate to very high activity against S. 
typhi and B. subtilis but weak to moderate activity against 
the other three bacterial strains tested. The presence of 
halogenated groups in the molecules had a great effect on 
the antibacterial potential of the synthesized molecules. 
Similarly, all the compounds proved to be very active 
against AChE. But above all, the urease inhibition 
potential of these compounds was very impressive 
compared to the standard used. Thus, the molecules with 
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FIGURE 4 - Fluorescence emission spectra of BSA and different amounts of selected compounds (7l, 7m, 7o, 7t, 7u) at 295 nm 
and 298 K (inset graph corresponding to the Stern-Volmer plot).
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FIGURE 5 - Double logarithm plots of compounds 7l, 7m, 7o, 7t and 7u.
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7l 1.8607 1.8607 1.8607 2.58 x 104 1.04
7m 0.8967 0.8967 0.8967 2.65 x 103 0.88
7o 0.8579 0.8579 0.8579 2.99 x 103 0.90
7t 1.1967 1.1967 1.1967 2.34 x 104 1.07
7u 2.1063 2.1063 2.1063 1.52 x 105 1.21
high bioactive potential could be considered for further 
in vivo studies and as candidates in drug discovery 
programs in the pharmaceutical industry.
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